Table 1

Baseline characteristics of the 4912 randomised participants, according to treatment group. Values are numbers (percentages) of patients unless stated otherwise

Ramipril (n=2443)Placebo (n=2469)
Sex (male, female)1701, 7421731, 738
Mean (SD) age (years)65.2 (8.4)65.0 (8.3)
Mean (SD) body mass index (kg/m2)29.2 (4.5)29.2 (4.7)
Mean (SD) fasting blood glucose (mmol/l)9.7 (3.1)9.9 (3.3)
Mean (SD) HbA1c (%)7.85 (1.82)7.79 (1.81)
Mean (SD) diabetes duration (years)9.8 (7.3)9.8 (7.5)
Mean (SD) systolic blood pressure (mm Hg)145.8 (15.0)145.1 (15.2)
Mean (SD) diastolic blood pressure (mmHg)82.4 (8.7)82.2 (8.5)
Hypertensive*1378 (56.4)1357 (55.0)
Smoker (≥1 cigarette/day)371 (15.2)385 (15.6)
Alcohol consumption (≥1 glass/day)1123 (46.0)1135 (46.0)
Mean (SD) serum creatinine (μmol/l)89.2 (20.7)89.2 (19.6)
Microalbuminuria (20-200 mg/l)1792 (73.4)1835 (74.3)
Proteinuria (≥200 μg/l)651 (26.6)634 (25.7)
Previous myocardial infarction137 (5.6)158 (6.4)
Peripheral vascular disease218 (8.9)285 (11.5)
Previous stroke107 (4.4)100 (4.1)
Previous retinopathy126 (5.2)120 (4.9)
No previous cardiovascular disease1895 (77.6)1816 (73.6)
Drug treatment:
Antihypertensive agents1158 (47.4)1184 (48.0)
Lipid lowering agents727 (29.8)674 (27.3)
Antiplatelets447 (18.3)472 (19.1)
  • * Blood pressure >140/90 mm Hg and/or taking antihypertensive drugs.

  • † Mean of two determinations.